120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
骨肉瘤中BLM和RECQL4上调：与不良预后、免疫细胞浸润及鞘氨醇激酶1抑制剂II/哌拉利西布抑制作用的关联
Authors Chen J , Situ Y, Cai J, Liao W, Jiang D, Huang C, Zheng J, Peng L, Lin H
Received 24 September 2025
Accepted for publication 16 January 2026
Published 22 January 2026 Volume 2026:15 569823
DOI https://doi.org/10.2147/ITT.S569823
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Michael Shurin
Jv Chen,1,* Yongli Situ,2,* Jie Cai,1 Wenyu Liao,1 Dongbo Jiang,1 Chengshuo Huang,2 Jinchang Zheng,2 Lijiao Peng,3 Hao Lin2
1Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524002, People’s Republic of China; 2Orthopedic Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524002, People’s Republic of China; 3Department of Digestive System Oncology, Oncology Hospital, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524002, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hao Lin, Orthopedic Center, Affiliated Hospital of Guangdong Medical University, No. 57 Renmin Avenue South, Zhanjiang, Guangdong, 524002, People’s Republic of China, Email linhao@gdmu.edu.cn Lijiao Peng, Department of Digestive System Oncology, Oncology Hospital, Affiliated Hospital of Guangdong Medical University, No. 57 Renmin Avenue South, Zhanjiang, Guangdong, 524002, People’s Republic of China, Email 244348566@qq.com
Purpose: BLM and RECQL4, key RecQ helicases and “genome guardians”, maintain genomic stability. Their abnormal function/dysregulated expression is linked to tumorigenesis, but their roles in osteosarcoma (OS) remain unclear.
Patients and Methods: Comprehensive bioinformatic analyses (multiple public databases) assess OS-related expression, gene networks, prognosis, targets, and drugs. Cellular experiments verified the effects of these compounds on 143B cell proliferation, migration, and invasion.
Results: BLM and RECQL4 were significantly upregulated in OS tissues compared to normal tissues, correlating with a poor prognosis. Among the 153 patients with OS, 9% and 7% had altered BLM and RECQL4 expression, respectively. Abnormal methylation of BLM and RECQL4 may affect OS. BLM, RECQL4, and their altered neighboring genes (ANGs) form interaction networks that regulate tumor metabolism, proliferation, migration, and apoptosis. Their miRNA and kinase targets in OS were also identified. BLM and RECQL4 expression was negatively correlated with OS immune cell infiltration. In addition, anti–PD-1/CTLA-4/PD-L1 therapy, Sphingosine kinase 1 inhibitor II, and pilaralisib inhibited OS cell viability (by downregulating BLM or RECQL4) and the proliferation, migration, and invasion of 143B cells. Knockdown of BLM or RECQL4 suppressed the migration and invasion of 143B cells.
Conclusion: BLM and RECQL4 are promising prognostic biomarkers and therapeutic targets for OS.
Keywords: BLM, RECQL4, osteosarcoma, gene regulatory network, immunotherapy, prognosis, biomarker, bioinformatics
1Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524002, People’s Republic of China; 2Orthopedic Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524002, People’s Republic of China; 3Department of Digestive System Oncology, Oncology Hospital, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524002, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hao Lin, Orthopedic Center, Affiliated Hospital of Guangdong Medical University, No. 57 Renmin Avenue South, Zhanjiang, Guangdong, 524002, People’s Republic of China, Email linhao@gdmu.edu.cn Lijiao Peng, Department of Digestive System Oncology, Oncology Hospital, Affiliated Hospital of Guangdong Medical University, No. 57 Renmin Avenue South, Zhanjiang, Guangdong, 524002, People’s Republic of China, Email 244348566@qq.com
Purpose: BLM and RECQL4, key RecQ helicases and “genome guardians”, maintain genomic stability. Their abnormal function/dysregulated expression is linked to tumorigenesis, but their roles in osteosarcoma (OS) remain unclear.
Patients and Methods: Comprehensive bioinformatic analyses (multiple public databases) assess OS-related expression, gene networks, prognosis, targets, and drugs. Cellular experiments verified the effects of these compounds on 143B cell proliferation, migration, and invasion.
Results: BLM and RECQL4 were significantly upregulated in OS tissues compared to normal tissues, correlating with a poor prognosis. Among the 153 patients with OS, 9% and 7% had altered BLM and RECQL4 expression, respectively. Abnormal methylation of BLM and RECQL4 may affect OS. BLM, RECQL4, and their altered neighboring genes (ANGs) form interaction networks that regulate tumor metabolism, proliferation, migration, and apoptosis. Their miRNA and kinase targets in OS were also identified. BLM and RECQL4 expression was negatively correlated with OS immune cell infiltration. In addition, anti–PD-1/CTLA-4/PD-L1 therapy, Sphingosine kinase 1 inhibitor II, and pilaralisib inhibited OS cell viability (by downregulating BLM or RECQL4) and the proliferation, migration, and invasion of 143B cells. Knockdown of BLM or RECQL4 suppressed the migration and invasion of 143B cells.
Conclusion: BLM and RECQL4 are promising prognostic biomarkers and therapeutic targets for OS.
Keywords: BLM, RECQL4, osteosarcoma, gene regulatory network, immunotherapy, prognosis, biomarker, bioinformatics